The company’s PhD research focused on using lasers for precise intracellular cargo delivery. However, conversations with 100+ industry experts revealed a more critical, and technically simpler, problem in cell therapy manufacturing: removing unwanted cells. This demonstrates the value of prioritizing market needs over scientific complexity.

A genetic diagnostics machine was built to speed up patient diagnosis in hospitals. However, its biggest market turned out to be pharmaceutical companies needing to prove drug efficacy. This highlights how true product-market fit can be discovered accidentally in an adjacent, more lucrative market.

Guardant's co-CEO argues that in complex fields like diagnostics, success hinges more on innovating the business model than the core technology. Superior tech fails if it doesn't align with the unique economic incentives where the user isn't the payer.

By initially focusing on the underserved SMB market, SmithRx built a highly repeatable and scalable platform. The operational rigor developed from handling thousands of smaller clients was the key to later "crossing the chasm" and successfully serving large, demanding enterprise customers.

Founders of platform technologies are often tempted to pursue many applications at once. A more effective strategy is to select and aggressively advance a single "beachhead program" to the clinic. This demonstrates the platform's value concretely, making it easier to attract funding and partners, while avoiding the dilution of resources.

Focusing on a single, narrow application limits long-term growth. By designing a scalable platform from the outset, MedTech companies can adapt their core technology to other procedures and markets, ensuring future viability and expansion opportunities.

Frontline Medical chose to develop the Cobra OS not because it was their most revolutionary concept, but because it was manufacturable with limited resources. They prioritized the idea that 'checked all the boxes' for feasibility, market success, and patient impact, ensuring they could bring a product to market.

Many companies fail by building a technology and then searching for a problem. VedaBio exemplifies the opposite approach: first defining the "perfect product" for a specific need (urgent care testing), and then applying the right technology to build it.

Instead of accepting biological limits, Guardant treated challenges like low DNA yield and high sequencing error rates as systems engineering and information processing problems. This reframing allowed for systematic, quantifiable solutions that competitors missed.